سعر أندوفلوزين إكس آر Andoflozin XR‏ 25/1000 مجم أقراص 2026

Empagliflozin + Metformin hydrochloride Empagliflozin 25 mg + metformin HCl 1000 mg (extended release) per tablet, extended-release film-coated tablets, pack of 20 (Andalous Pharma, Egypt).

• Empagliflozin: urinary tract infections and female genital mycotic infections (>=5%). Metformin: diarrhoea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (>5%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR <30 mL/min/1.73 m2); metabolic acidosis including diabetic ketoacidosis; hypersensitivity to empagliflozin, metformin or excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metformin-associated lactic acidosis (risk factors: renal impairment, age >=65, contrast studies, surgery, hypoxia, excess alcohol, hepatic impairment).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Ketoacidosis (assess regardless of glucose), volume depletion, genitourinary infections including urosepsis and Fournier gangrene, hypoglycaemia with insulin/secretagogues, lower-limb amputation, hypersensitivity, vitamin B12 deficiency.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Carbonic anhydrase inhibitorsMay increase risk of lactic acidosis; consider more frequent monitoring.DailyMed (U.S. National Library of Medicine)
• Drugs that reduce metformin clearanceMay increase risk of lactic acidosis; weigh benefits and risks.DailyMed (U.S. National Library of Medicine)

• Advise females of potential risk to a fetus, especially during the second and third trimesters.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not recommended when breastfeeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).